Table. Type of ICH and Clinical Outcomes Among Included Studies.
| Source | Type of ICH, No./total No. (%)a | Outcomes, No./total No. (%) | |||||
|---|---|---|---|---|---|---|---|
| SAH | SDH | Others (IPH/IVH/ICerH) | Traumatic ICH | Anticoagulation reversalb | Mortality | TE events | |
| 4-Factor PCC | |||||||
| Grandhi et al,24 2015 | 4/18 (22) | 4/18 (22) | 12/18 (67) | 8/18 (44) | 17/18 (94) | 6/18 (33) | 1/18 (6) |
| Majeed et al,25 2017 | NR | NR | NR | NR | 43/59 (73) | 13/59 (22) | 3/59 (5) |
| Gerner et al,8 2018 | NR | NR | NR | NR | 61/94 (65) | NR | NR |
| Schulman et al,26 2017 | NR | NR | NR | NR | 30/36 (83) | 8/36 (22) | NR |
| Tao et al,27 2018 | NR | NR | NR | NR | NR | NR | 1/16 (6) |
| Sheikh-Taha,28 2019 | NR | NR | NR | NR | 13/21 (62) | 6/21 (29) | 1/21 (5) |
| Smith et al,29 2019 | 4/18 (22) | 7/18 (39) | 7/18 (39) | 13/18 (72) | 16/18 (89) | NR | 0/18 |
| Berger et al,30 2020 | 7/22 (32) | 5/22 (23) | 7/22 (32) | NR | 18/19 (95) | 4/22 (18) | 2/22 (9) |
| Zheng and Tormey,31 2020 | NR | NR | NR | NR | 8/9 (89) | 4/13 (31) | NR |
| Korobey et al,32 2021 | 5/59 (8) | 20/59 (34) | 34/59 (58) | 31/59 (53) | 52/59 (88) | 6/59 (10) | 7/59 (12) |
| Castillo et al,33 2021 | 10/67 (15) | 25/67 (37) | 30/67 (45) | 44/67 (66) | 59/67 (88) | 5/67 (7) | 0/67 |
| Lipari et al,34 2020 | 13/85 (15) | 25/85 (29) | 47/85 (55) | NR | 72/85 (85) | 12/85 (14) | 2/85 (2) |
| Barra et al,35 2020 | 0/11 | 3/11 (27) | 8/11 (73) | 5/11 (45) | 6/10 (60) | 7/11 (64) | 1/11 (9) |
| Coleman et al,36 2021 | NR | NR | NR | NR | NR | 43/170 (25) | NR |
| Ammar et al,37 2021 | 0/16 | 0/16 | 13/16 (81) | 8/16 (50) | 6/10 (60) | 6/16 (38) | 0/16 |
| Smythe et al,38 2021 | 4/34 (12) | 13/34 (38) | 17/34 (50) | NR | 21/29 (72) | 6/34 (18) | 3/34 (9) |
| Stevens et al,39 2021 | NR | NR | NR | NR | 7/10 (70) | 4/10 (40) | NR |
| Pasciolla et al,45 2022 | 8/44 (18) | 14/44 (32) | 19/44 (43) | NR | 14/19 (74) | 18/44 (41) | 5/44 (11) |
| Pham et al,40 2022 | 13/62 (21) | 23/62 (37) | 58/62 (94) | NR | 46/58 (79) | 13/62 (21) | 6/62 (10) |
| Parsels et al,41 2022 | 11/26 (42) | 5/26 (19) | 9/26 (35) | 18/26 (69) | 23/26 (88) | NR | 3/26 (12) |
| Milioglou et al,42 2022 | 1/22 (5) | 4/22 (18) | 17/22 (77) | NR | NR | 10/22 (45) | 0/22 |
| Dev et al,43 2022 | NR | NR | NR | NR | 14/20 (70) | NR | NR |
| Vestal et al,44 2022 | 6/35 (17) | 1/35 (3) | 28/35 (80) | 11/35 (31) | 17/31 (55) | 13/35 (37) | 10/35 (29) |
| Andexanet alfa | |||||||
| Connolly et al,13 2019; Demchuk et al,50 2021 | 43/171 (25) | 58/171 (34) | 104/171 (61) | 72/171 (42) | 135/168 (80) | 34/227 (15) | 21/227 (9) |
| Stevens et al,46 2019 | NR | NR | NR | NR | 3/6 (50) | 2/6 (33) | NR |
| Culbreth et al,49 2019 | 4/14 (29) | 5/14 (36) | 9/14 (64) | NR | 8/14 (57) | 5/14 (36) | NR |
| Brown et al,47 2020 | 1/13 (8) | 2/13 (15) | 10/13 (77) | NR | 10/11 (91) | 4/13 (31) | 0/13 |
| Barra et al,35 2020 | 1/18 (6) | 5/18 (28) | 12/18 (67) | 12/18 (67) | 16/18 (89) | 4/18 (22) | 3/18 (17) |
| Coleman et al,36 2021 | NR | NR | NR | NR | NR | 6/67 (9) | NR |
| Giovino et al,48 2020 | 4/39 (10) | 16/39 (41) | 19/39 (49) | 24/39 (62) | 29/39 (74) | 4/35 (11) | 2/35 (6) |
| Ammar et al,37 2021 | 2/28 (7) | 1/28 (4) | 25/28 (89) | 8/28 (29) | 15/28 (54) | 11/28 (39) | 2/28 (7) |
| Stevens et al,39 2021 | NR | NR | NR | NR | 4/7 (57) | NR | NR |
| Sobolewski et al,51 2021 | 1/7 (14) | 1/7 (14) | 5/7 (71) | NR | 5/7 (71) | 3/7 (43) | 2/7 (29) |
| Benz et al,52 2022 | NR | NR | NR | 7/38 (18) | 31/38 (82) | NR | NR |
| Pham et al,40 2022 | 12/47 (26) | 14/47 (30) | 46/47 (98) | NR | 31/38 (82) | 16/47 (34) | 4/47 (9) |
| Parsels et al,41 2022 | 9/26 (35) | 5/26 (19) | 12/26 (46) | 16/26 (62) | 24/26 (92) | NR | 7/26 (27) |
| Milioglou et al,42 2022 | 0/23 | 4/23 (17) | 19/23 (83) | NR | NR | 11/23 (48) | 0/23 |
| Vestal et al,44 2022 | 2/21 (10) | 2/21 (10) | 17/21 (81) | 5/21 (24) | 11/17 (65) | 3/21 (14) | 3/21 (14) |
| Idarucizumab | |||||||
| Pollack et al,12 2017 | 26/98 (27) | 39/98 (40) | 53/98 (54) | NR | NR | 9/98 (9) | 5/98 (5) |
| Sheikh-Taha et al,53 2019 | NR | NR | NR | 2/6 (33) | 4/6 (67) | 0/6 | 0/6 |
| Singh et al,54 2020 | NR | NR | NR | NR | NR | 13/112 (12) | 1/112 (1) |
| Kermer et al,55 2020 | 2/40 (5) | 11/40 (28) | 27/40 (68) | NR | 24/27 (89) | 6/40 (15) | NR |
| Yasaka et al,56 2020 | 25/84 (30) | 34/84 (40) | 47/84 (56) | NR | NR | 9/84 (11) | 5/84 (6) |
Abbreviations: ICerH, intracerebral hemorrhage; ICH, intracranial hemorrhage; IPH, intraparenchymal hemorrhage; IVH, intraventricular hemorrhage; NR, not reported; PCC, prothrombin complex concentrate; SAH, subarachnoid hemorrhage; SDH, subdural hematoma; TE, thromboembolic.
a
Numbers add up to more than 100% since concomitant bleeding was present in more than one compartment.
b
If computed tomography head stability was measured at different time frames, hemostatic efficacy was calculated using the values for 24-hour after reversal agent administration to reduce heterogeneity in outcomes.